GenAI could aid clinical trial design, feasibility and site selection, patient recruitment, analysis and regulatory submission.

The trial enrolled ten Georgian subjects living with advancing acute decompensated heart failure and was able to drain 4.8l fluid among them.

Bristol Myers Squibb’s Cobenfy is the first treatment in seven decades that does not modulate dopaminergic or serotonergic transmission.

Research carried out by PureTech found that daily doses of deupirfenidone could slow the degeneration of the lungs in patients.

Incyclix Bio has reported outcomes from the dose escalation part of the Phase I/II INX-315-01 trial of INX-315 for breast cancer treatment.

BrightPath and Cellistic have entered an agreement to progress the CAR-T cell therapy platform into clinical trials.